Teva's (TEVA) TREANDA Approved by US FDA StreetInsider.com (subscription) TREANDA is indicated for use in patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen, and in patients with chronic lymphocytic leukemia ... |
